{"filing":{"accession_number":"0001213900-26-096113","cik":"0001415397","ticker":"RAPH","company_name":"Raphael Pharmaceutical Inc.","form":"8-K","filing_date":"2026-09-01","report_date":"2026-07-30","primary_document":"ea0304182-8k_raphael.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1415397/000121390026096113/ea0304182-8k_raphael.htm"},"events":[{"id":30893,"run_id":28328,"accession_number":"0001213900-26-096113","anchor_item_number":"1.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"The disclosure describes entry into a material managed-services agreement with AIcreatesAI for AI transformation, digital operations, and growth support at $180,000 annually. While Item 1.01 typically covers M\u0026A activity, this is a strategic operational partnership and services contract rather than an acquisition, merger, or change of control. The agreement is material to investors as it signals a significant operational and strategic pivot toward AI-driven transformation and includes provisions for deferred payment and potential equity issuance, but does not fit the specific M\u0026A taxonomy categories.","company_name":"Raphael Pharmaceutical Inc.","ticker":"RAPH","filing_date":"2026-09-01","form":"8-K","submitted_at":null,"items":[{"id":33631,"accession_number":"0001213900-26-096113","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"The disclosure describes entry into a material managed-services agreement with AIcreatesAI for AI transformation, digital operations, and growth support at $180,000 annually. While Item 1.01 typically covers M\u0026A activity, this is a strategic operational partnership and services contract rather than an acquisition, merger, or change of control. The agreement is material to investors as it signals a significant operational and strategic pivot toward AI-driven transformation and includes provisions for deferred payment and potential equity issuance, but does not fit the specific M\u0026A taxonomy categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T16:52:46.349763+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33631,"accession_number":"0001213900-26-096113","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"The disclosure describes entry into a material managed-services agreement with AIcreatesAI for AI transformation, digital operations, and growth support at $180,000 annually. While Item 1.01 typically covers M\u0026A activity, this is a strategic operational partnership and services contract rather than an acquisition, merger, or change of control. The agreement is material to investors as it signals a significant operational and strategic pivot toward AI-driven transformation and includes provisions for deferred payment and potential equity issuance, but does not fit the specific M\u0026A taxonomy categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T16:52:46.349763+00:00","company_name":"Raphael Pharmaceutical Inc.","ticker":"RAPH","filing_date":"2026-09-01"}]}